

ALCHEMY PHARMATECH LIMITED

Unaudited Abbreviated Accounts

for the Year Ended 31 March 2014

CEJ Accounts Ltd
Chartered Management Accountants
17 SOUTH DRIVE
UPTON
WIRRAL
Wirral
CH49 6LA

ALCHEMY PHARMATECH LIMITED
Contents

Abbreviated Balance Sheet



1

Notes to the Abbreviated Accounts

2 to 3

ALCHEMY PHARMATECH LIMITED
(Registration number: 07912825)
Abbreviated Balance Sheet at 31 March 2014

	Note	31 March 2014 £	31 March 2013 £
Fixed assets			
Intangible fixed assets		242,456	213,302
Current assets			
Debtors		30,268	44,266
Cash at bank and in hand		14,102	106,563
		44,370	150,829
Creditors: Amounts falling due within one year		(8,229)	(27,325)
Net current assets		36,141	123,504
Net assets		278,597	336,806
Capital and reserves			
Called up share capital	<u>3</u>	425,075	400,122
Profit and loss account		(146,478)	(63,316)
Shareholders' funds		278,597	336,806

For the year ending 31 March 2014 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime .

Approved by the Board on 23 December 2014 and signed on its behalf by:

.....
Mr P I Harrison
Director

The notes on pages 2 to 3 form an integral part of these financial statements.

ALCHEMY PHARMATECH LIMITED
Notes to the Abbreviated Accounts for the Year Ended 31 March 2014
..... continued

1 Accounting policies

Basis of preparation

The full financial statements, from which these abbreviated accounts have been extracted, have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (Effective April 2008).

Goodwill

Positive goodwill is capitalised, classified as an asset on the balance sheet and amortised on a straight line basis over its useful economic life. It is reviewed for impairment at the end of the first full financial year following the acquisition and in other periods if events or changes in circumstances indicate that the carrying value may not be recoverable.

Amortisation

Amortisation is provided on intangible fixed assets so as to write off the cost, less any estimated residual value, over their expected useful economic life as follows:

Asset class	Amortisation method and rate
Research and development costs	0%

Research and development

Development expenditure incurred on an individual project is carried forward when its future recoverability can reasonably be regarded as assured. Any expenditure carried forward is amortised in line with the expected future sales from the related project.

Hire purchase and leasing

Rentals payable under operating leases are charged in the profit and loss account on a straight line basis over the lease term.

Financial instruments

Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the company is presented as a liability in the balance sheet. The corresponding dividends relating to the liability component are charged as interest expense in the profit and loss account.

ALCHEMY PHARMATECH LIMITED
Notes to the Abbreviated Accounts for the Year Ended 31 March 2014
..... continued

2 Fixed assets

	Intangible assets £	Total £
Cost		
At 1 April 2013	213,302	213,302
Additions	<u>29,154</u>	<u>29,154</u>
At 31 March 2014	242,456	242,456
Depreciation		
At 31 March 2014	<u>-</u>	<u>-</u>
Net book value		
At 31 March 2014	<u>242,456</u>	<u>242,456</u>
At 31 March 2013	<u>213,302</u>	<u>213,302</u>

3 Share capital

Allotted, called up and fully paid shares

	31 March 2014		31 March 2013	
	No.	£	No.	£
Ordinary of £0.01 each	10,000	100	10,000	100
Ordinary A of £54.13 each	7,390	400,021	7,390	400,021
Ordinary B of £54.13 (2013 - £0.00) each	<u>461</u>	<u>24,954</u>	<u>-</u>	<u>-</u>
	<u>17,851</u>	<u>425,075</u>	<u>17,390</u>	<u>400,121</u>

New shares allotted

During the year 461 Ordinary B having an aggregate nominal value of £54 were allotted for an aggregate consideration of £ 24,954.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.